CHI3L1 and LCN2 have previously been identified as immune-related biomarkers for disease outcome in breast cancer patients as well as for monitoring tumor progression in the intraductal mouse model for TNBC [6, 12–14]. Here, CHI3L1 is linked to neoplasm.